Professor Ji Jiafu: Gastric and Gastroesophageal Cancer Specialist
Professor Ji Jiafu is a senior surgical oncologist, professor, doctoral supervisor, and former president of Peking University Cancer Hospital. He is internationally recognized for clinical and translational work in gastric cancer, gastroesophageal junction cancer, multidisciplinary treatment, and precision surgery.
His work focuses on improving diagnosis, surgical quality, treatment sequencing, lymph-node management, molecular classification, and long-term outcomes for patients with gastric malignancies.
International patients can learn more about the hospital, pathology requirements, and treatment planning in our Peking University Cancer Hospital international patient guide.
Clinical and Academic Focus
Professor Ji’s principal areas include:
- gastric adenocarcinoma;
- gastroesophageal junction cancer;
- locally advanced gastric cancer;
- gastric cancer surgery and lymph-node dissection;
- multidisciplinary treatment planning;
- perioperative chemotherapy;
- molecular classification and precision oncology;
- recurrent or metastatic gastric cancer review; and
- second opinions before major upper gastrointestinal surgery.
Gastric Cancer
Gastric cancer most often arises from the glandular lining of the stomach. Symptoms may include persistent upper abdominal discomfort, early fullness, reduced appetite, anemia, weight loss, vomiting, bleeding, or difficulty swallowing, although early disease can cause few symptoms.
Accurate staging is essential before treatment. Evaluation may include upper endoscopy, biopsy, contrast-enhanced CT, endoscopic ultrasound, PET-CT in selected cases, and diagnostic laparoscopy with peritoneal washing for some locally advanced tumors.
Treatment depends on tumor depth, lymph-node involvement, location, molecular findings, spread, nutritional status, and general health.
Early Gastric Cancer
Selected early gastric cancers can be removed through endoscopy, avoiding major surgery. Suitability depends on tumor size, ulceration, histology, depth, and estimated risk of lymph-node spread.
When the risk exceeds accepted endoscopic criteria, gastrectomy with lymph-node dissection may be recommended. Pathology review is central to determining whether endoscopic treatment was curative or whether additional surgery should be considered.
Locally Advanced Gastric Cancer
Locally advanced gastric cancer often requires a combination of systemic treatment and surgery. Chemotherapy may be given before surgery, after surgery, or both, depending on the stage, treatment protocol, and patient’s condition.
Professor Ji has led and participated in clinical research evaluating perioperative strategies and surgical quality. Treatment sequencing should be discussed by a multidisciplinary team because proceeding directly to surgery is not always the best approach.
Gastric Cancer Surgery
Surgery may involve removal of part or all of the stomach together with regional lymph nodes. The operation is chosen according to tumor location, required margins, lymphatic drainage, and patient factors.
Minimally invasive laparoscopic or robotic techniques may be appropriate in selected cases. The surgical approach should not compromise cancer clearance or lymph-node assessment.
Potential consequences include weight loss, nutritional deficiencies, altered eating patterns, dumping symptoms, anemia, reflux, and changes in blood glucose. Nutrition planning and long-term monitoring are important parts of care.
Gastroesophageal Junction Cancer
Gastroesophageal junction cancers arise near the point where the esophagus meets the stomach. Their classification and treatment can be complex because surgical and oncology strategies may differ according to the tumor’s center and extent.
Evaluation should define involvement of the esophagus, stomach, lymph nodes, and nearby structures. Treatment may include chemotherapy, chemoradiotherapy, surgery, targeted therapy, immunotherapy, or a combination.
Molecular Testing and Precision Treatment
Advanced gastric cancer may be tested for biomarkers such as HER2, mismatch repair or microsatellite instability, PD-L1, CLDN18.2, and other clinically relevant alterations. Results can influence targeted or immune treatment options.
Testing methods, scoring, tissue quality, and regulatory approval matter. A biomarker does not guarantee benefit, and the availability of a medicine or clinical trial varies.
Research and Academic Contributions
Professor Ji has led major research programs in gastric cancer surgery, molecular classification, treatment standardization, and multidisciplinary care. His work has included large clinical cohorts, translational studies, and randomized or prospective investigations intended to improve outcomes for locally advanced disease.
Clinical-trial findings should be interpreted according to tumor stage, treatment regimen, patient selection, and current guidelines. They do not automatically establish one approach as suitable for every patient.
Who May Consider a Consultation?
A consultation with Professor Ji or the Peking University Cancer Hospital gastrointestinal team may be worth considering when a patient:
- has newly diagnosed gastric or gastroesophageal junction cancer;
- needs a second opinion on endoscopic treatment versus surgery;
- has locally advanced disease requiring treatment sequencing;
- needs review of lymph-node dissection or surgical extent;
- has received conflicting recommendations about chemotherapy before surgery;
- has recurrent or metastatic gastric cancer;
- needs molecular and pathology review; or
- requires a multidisciplinary treatment plan.
Medical Records to Prepare
International patients should prepare:
- a concise medical summary and treatment timeline;
- endoscopy and endoscopic ultrasound reports, images, and videos;
- contrast-enhanced CT, PET-CT, or MRI in original DICOM format;
- pathology reports, glass slides, and paraffin blocks;
- HER2, mismatch repair, PD-L1, CLDN18.2, and molecular test results when available;
- operative and diagnostic-laparoscopy records;
- chemotherapy and radiotherapy details, including dose and response;
- recent blood count, liver and kidney function, tumor markers, and nutritional assessment;
- a complete medication list; and
- a clear list of questions about stage, treatment sequence, and surgery.
Original imaging and pathology materials are essential because staging and treatment recommendations may change after specialist review.
Planning an International Consultation
Before traveling, patients should confirm whether imaging and pathology can be reviewed, whether an in-person examination is required, and whether further staging is needed.
Remote medical-record review is subject to physician authorization. It may help clarify the next step, but final treatment eligibility, surgical approach, expected hospital stay, and cost require complete assessment by the treating team.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, imaging, and pathology; identifying an appropriate specialist; requesting appointment availability; arranging interpretation; and planning medical travel in China.
Access to Professor Ji, remote review, surgery, molecular treatment, or clinical trials is subject to the doctor’s and hospital’s approval. CMCS does not guarantee appointments, treatment eligibility, or clinical outcomes.
For assistance, contact CMCS:
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor titles, clinical roles, biomarker requirements, treatment availability, and appointment arrangements may change. Patients should confirm current information before travel. This profile is based on publicly available hospital and academic sources and is provided for general information only. It is not individual medical advice and does not replace assessment by a qualified oncology team.
0 comentarios